Successful therapeutic use of rituximab in refractory membranous glomerulonephritis
| Autor: | D Hernández, M Cobo, L Pérez-Tamajón, C Rodriguez |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Male
medicine.medical_specialty Nephrotic Syndrome Time Factors Idiopathic membranous glomerulonephritis Angiotensin II receptor antagonist Glomerulonephritis Membranous Gastroenterology Antibodies Monoclonal Murine-Derived immune system diseases Prednisone hemic and lymphatic diseases Internal medicine medicine Humans Immunologic Factors B-Lymphocytes Proteinuria Chlorambucil business.industry Antibodies Monoclonal Glomerulonephritis General Medicine Middle Aged Antigens CD20 medicine.disease Nephrology Immunology Rituximab medicine.symptom business Nephrotic syndrome medicine.drug |
| Zdroj: | Clinical Nephrology. 66:54-57 |
| ISSN: | 0301-0430 |
| DOI: | 10.5414/cnp66054 |
| Popis: | We present the case of a 57-year-old man with nephrotic syndrome secondary to idiopathic membranous glomerulonephritis unsuccessfully treated with angiotensin-converting enzyme inhibitor (ACEI), angiotensin II receptor antagonist (ARA), prednisone and chlorambucil. After treatment with rituximab, we observed a progressive decrease of proteinuria and normalization of serum albumin. 18 months after treatment, he remained in remission. No adverse reactions to rituximab were noted throughout follow-up. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|